Related Experiment Video
Updated: Dec 13, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
SRC-Family Kinases in Acute Myeloid Leukaemia and Mastocytosis
Edwige Voisset1, Fabienne Brenet1, Sophie Lopez1
1INSERM U1068, CNRS UMR7258, Aix-Marseille Université UM105, Institute Paoli-Calmettes, CRCM-Cancer Research Center of Marseille, U1068 Marseille, France.
Abstract:
Protein tyrosine kinases have been recognized as important actors of cell transformation and cancer progression, since their discovery as products of viral oncogenes. SRC-family kinases (SFKs) play crucial roles in normal hematopoiesis. Not surprisingly, they are hyperactivated and are essential for membrane receptor downstream signaling in hematological malignancies such as acute myeloid leukemia (AML) and mastocytosis. The precise roles of SFKs are difficult to delineate due to the number of substrates, the functional redundancy among members, and the use of tools that are not selective. Yet, a large num ber of studies have accumulated evidence to support that SFKs are rational therapeutic targets in AML and mastocytosis. These two pathologies are regulated by two related receptor tyrosine kinases, which are well known in the field of hematology: FLT3 and KIT. FLT3 is one of the most frequently mutated genes in AML, while KIT oncogenic mutations occur in 80-90% of mastocytosis. Studies on oncogenic FLT3 and KIT signaling have shed light on specific roles for members of the SFK family. This review highlights the central roles of SFKs in AML and mastocytosis, and their interconnection with FLT3 and KIT oncoproteins.
Related Concept Videos
MAPK Signaling Cascades
Abnormal Proliferation
Intracellular Signaling Affects Focal Adhesions
Some...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Differentiation of Common Myeloid Progenitor Cells
Amplifying Signals via Enzymatic Cascade

